Tenofovir disoproxil fumarate, emtricitabine, and efavirenz compared with zidovudine/lamivudine and efavirenz in treatment-naive patients

144-Week analysis

Jose R. Arribas, Anton L. Pozniak, Joel E. Gallant, Edwin DeJesus, Brian Gazzard, Rafael E. Campo, Shan Shan Chen, Damian McColl, Charles Holmes, Jeffrey Enejosa, John J. Toole, Andrew K. Cheng

Research output: Contribution to journalArticle

Abstract

BACKGROUND: As antiretroviral regimens for the treatment of HIV infection improve, trials providing data on long-term follow-up are increasingly important. METHODS: A regimen of tenofovir disoproxil fumarate (TDF), emtricitabine (FTC), and efavirenz (EFV) demonstrated superior virologic, immunologic and morphologic effects compared with a regimen of fixed-dose zidovudine/lamivudine (ZDV/3TC) and EFV through 96 weeks in a randomized open-label trial. After 96 weeks, patients on TDF + FTC transitioned to fixed-dose combination TDF/FTC. RESULTS: Through 144 weeks, significantly more patients in the TDF/FTC arm reached and maintained an HIV RNA level

Original languageEnglish (US)
Pages (from-to)74-78
Number of pages5
JournalJournal of Acquired Immune Deficiency Syndromes
Volume47
Issue number1
DOIs
StatePublished - Jan 2008
Externally publishedYes

Fingerprint

Tenofovir
efavirenz
Lamivudine
Zidovudine
Therapeutics
HIV Infections
HIV
RNA
Emtricitabine

Keywords

  • Antiretroviral naive
  • Emtricitabine
  • Lamivudine
  • Lipoatrophy
  • Tenofovir
  • Zidovudine

ASJC Scopus subject areas

  • Virology
  • Immunology

Cite this

Tenofovir disoproxil fumarate, emtricitabine, and efavirenz compared with zidovudine/lamivudine and efavirenz in treatment-naive patients : 144-Week analysis. / Arribas, Jose R.; Pozniak, Anton L.; Gallant, Joel E.; DeJesus, Edwin; Gazzard, Brian; Campo, Rafael E.; Chen, Shan Shan; McColl, Damian; Holmes, Charles; Enejosa, Jeffrey; Toole, John J.; Cheng, Andrew K.

In: Journal of Acquired Immune Deficiency Syndromes, Vol. 47, No. 1, 01.2008, p. 74-78.

Research output: Contribution to journalArticle

Arribas, Jose R. ; Pozniak, Anton L. ; Gallant, Joel E. ; DeJesus, Edwin ; Gazzard, Brian ; Campo, Rafael E. ; Chen, Shan Shan ; McColl, Damian ; Holmes, Charles ; Enejosa, Jeffrey ; Toole, John J. ; Cheng, Andrew K. / Tenofovir disoproxil fumarate, emtricitabine, and efavirenz compared with zidovudine/lamivudine and efavirenz in treatment-naive patients : 144-Week analysis. In: Journal of Acquired Immune Deficiency Syndromes. 2008 ; Vol. 47, No. 1. pp. 74-78.
@article{c16500ca48b0447697e5a568719e6dbf,
title = "Tenofovir disoproxil fumarate, emtricitabine, and efavirenz compared with zidovudine/lamivudine and efavirenz in treatment-naive patients: 144-Week analysis",
abstract = "BACKGROUND: As antiretroviral regimens for the treatment of HIV infection improve, trials providing data on long-term follow-up are increasingly important. METHODS: A regimen of tenofovir disoproxil fumarate (TDF), emtricitabine (FTC), and efavirenz (EFV) demonstrated superior virologic, immunologic and morphologic effects compared with a regimen of fixed-dose zidovudine/lamivudine (ZDV/3TC) and EFV through 96 weeks in a randomized open-label trial. After 96 weeks, patients on TDF + FTC transitioned to fixed-dose combination TDF/FTC. RESULTS: Through 144 weeks, significantly more patients in the TDF/FTC arm reached and maintained an HIV RNA level",
keywords = "Antiretroviral naive, Emtricitabine, Lamivudine, Lipoatrophy, Tenofovir, Zidovudine",
author = "Arribas, {Jose R.} and Pozniak, {Anton L.} and Gallant, {Joel E.} and Edwin DeJesus and Brian Gazzard and Campo, {Rafael E.} and Chen, {Shan Shan} and Damian McColl and Charles Holmes and Jeffrey Enejosa and Toole, {John J.} and Cheng, {Andrew K.}",
year = "2008",
month = "1",
doi = "10.1097/QAI.0b013e31815acab8",
language = "English (US)",
volume = "47",
pages = "74--78",
journal = "Journal of Acquired Immune Deficiency Syndromes",
issn = "1525-4135",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Tenofovir disoproxil fumarate, emtricitabine, and efavirenz compared with zidovudine/lamivudine and efavirenz in treatment-naive patients

T2 - 144-Week analysis

AU - Arribas, Jose R.

AU - Pozniak, Anton L.

AU - Gallant, Joel E.

AU - DeJesus, Edwin

AU - Gazzard, Brian

AU - Campo, Rafael E.

AU - Chen, Shan Shan

AU - McColl, Damian

AU - Holmes, Charles

AU - Enejosa, Jeffrey

AU - Toole, John J.

AU - Cheng, Andrew K.

PY - 2008/1

Y1 - 2008/1

N2 - BACKGROUND: As antiretroviral regimens for the treatment of HIV infection improve, trials providing data on long-term follow-up are increasingly important. METHODS: A regimen of tenofovir disoproxil fumarate (TDF), emtricitabine (FTC), and efavirenz (EFV) demonstrated superior virologic, immunologic and morphologic effects compared with a regimen of fixed-dose zidovudine/lamivudine (ZDV/3TC) and EFV through 96 weeks in a randomized open-label trial. After 96 weeks, patients on TDF + FTC transitioned to fixed-dose combination TDF/FTC. RESULTS: Through 144 weeks, significantly more patients in the TDF/FTC arm reached and maintained an HIV RNA level

AB - BACKGROUND: As antiretroviral regimens for the treatment of HIV infection improve, trials providing data on long-term follow-up are increasingly important. METHODS: A regimen of tenofovir disoproxil fumarate (TDF), emtricitabine (FTC), and efavirenz (EFV) demonstrated superior virologic, immunologic and morphologic effects compared with a regimen of fixed-dose zidovudine/lamivudine (ZDV/3TC) and EFV through 96 weeks in a randomized open-label trial. After 96 weeks, patients on TDF + FTC transitioned to fixed-dose combination TDF/FTC. RESULTS: Through 144 weeks, significantly more patients in the TDF/FTC arm reached and maintained an HIV RNA level

KW - Antiretroviral naive

KW - Emtricitabine

KW - Lamivudine

KW - Lipoatrophy

KW - Tenofovir

KW - Zidovudine

UR - http://www.scopus.com/inward/record.url?scp=39049101609&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=39049101609&partnerID=8YFLogxK

U2 - 10.1097/QAI.0b013e31815acab8

DO - 10.1097/QAI.0b013e31815acab8

M3 - Article

VL - 47

SP - 74

EP - 78

JO - Journal of Acquired Immune Deficiency Syndromes

JF - Journal of Acquired Immune Deficiency Syndromes

SN - 1525-4135

IS - 1

ER -